Purple Biotech announced that its lead tri-specific antibody candidate, IM1240, from the CAPTN-3 platform, will be presented orally at the 38th EORTC-NCI-AACR Symposium in Barcelona on November 20, 2026. The presentation will highlight IM1240's effectiveness in treatment-resistant tumor models and its safety profile. This marks a significant step as Purple Biotech prepares to complete IND-enabling studies and aims to start first-in-human clinical trials in 2027, advancing their next-generation immunotherapy approach that targets tumors while minimizing toxicity.
Purple Biotech's IM1240 gains context from today's Health-sector market activity on Pluang, where 91 of 150 priced US stocks rose. For readers following Health stocks, here is Pluang's market snapshot as of Oct 29, 2026 19:12 WIB: Mesoblast Limited (MESO) surged 18.22% to USD 15.83 with a typical hold time of 17 days, Haleon plc (HLN) dropped 13.80% to USD 8.62 with a 15-day hold, and Teladoc Health Inc (TDOC) rose 11.34% to USD 7.66 with a 39-day hold time.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
